

## Partnering Opportunity

Profile Status: Published

### Technology Offer

---

## Novel therapeutic approach in a multiplicity of neurodegenerative and autoinflammatory pathologies

---

### Summary

---

*An Italian research group has developed new therapeutic approaches to neurodegenerative and autoinflammatory pathologies. The research group is interested in finding partners for developing the research targeting neurological diseases. Partners may be pharmaceutical companies, startup or other research groups interested in research collaborations, in technical or research cooperation agreements or in financial agreements for future developments of a product.*

**Creation Date** 19 April 2019  
**Expiration Date** 07 May 2020  
**Reference** TOIT20190416001

---

### Details

---

#### Description

Recent findings have highlighted the important role played by the disregulated activation of the innate immune system in the onset and progression of several neurological and autoinflammatory diseases. Small organic molecules able to modulate the activation of the immune system have, therefore, a great potential in the identification of a therapeutic approach for a multiplicity of neurodegenerative and autoinflammatory pathologies. The inhibition of the caspase-1 enzyme may allow to modulate the release of proinflammatory cytokines deriving from the activation of the inflammasome, blocking the inflammatory process. To date, there are no caspase-1 inhibitors that can be used in the clinic. In fact, although numerous caspase-1 inhibitors have been synthesized, no inhibitor has passed the clinical trial, probably because of the covalent mechanism of action and the consequent unwanted off-target interactions. The research group, in collaboration with a foreign University, is interested in finding possible partners with whom to complete the pre-clinical study and further develop the technology through technical or research cooperation agreements or financial agreements.

### Advantages and Innovations

The research result and patent related, claims a new class of molecules able to inhibit caspase-1 to modulate innate immune system and in inflammatory processes. The new molecules discovered present innovative characteristics, with respect to the molecules currently known, because of their non-covalent mechanism of action.

### Stage of Development

Under development/lab tested

### IPR Status

Patent(s) applied for but not yet granted

### Profile Origin

National or Regional R&D programme

---

## Network Contact

---

### Issuing Partner

AGENCIA ANDALUZA DEL CONOCIMIENTO

### Contact Person

María Fernández Santa Cruz Campos

### Email

maria.fernandezsantacruz@juntadeandalucia.es

---

**Open for EOI :**    **Yes**

---

---

## Dissemination

---

### Relevant Sector Groups

Healthcare

---

## Client

---

**Type and Size of Organisation Behind the Profile**

R&D Institution

**Year Established**

0

**Already Engaged in Trans-National Cooperation**

Yes

**Languages Spoken**

English  
Italian

**Client Country**

Italy

---

**Partner Sought**

---

**Type and Role of Partner Sought**

Pharmaceutical companies interested in further developing the product.

**Type of Partnership Considered**

Financial agreement  
Technical cooperation agreement  
Research cooperation agreement